Analyst consensus rating
Prime Medicine Analyst Rating: Buy
PRME is rated Buy by 11 analysts with a $7.30 target. As of 2026-08-25.
Direct answer
Prime Medicine's consensus rating is Buy.
11 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $7.30.
Forecast evidence checked August 25, 2026.
Get free Prime Medicine email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $3.62
- Average price target
- $7.30
- High price target
- $11.00
- Low price target
- $4.25
- Low target gap
- +17.6%
- Target upside
- +101.8%
- High target gap
- +204.3%
- Target range width
- 186.7%
- Consensus rating
- Buy
- Analysts
- 11
- Evidence date
- August 25, 2026
- Valid through
- September 1, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Prime Medicine?
Prime Medicine has a verified Buy consensus. The same dataset has an average price target of $7.30.
How far are Prime Medicine's low and high targets from the recorded price?
The low target implies +17.6%, while the high target implies +204.3%.
How many analysts are included in Prime Medicine's consensus?
The verified consensus includes 11 analysts.
How is Prime Medicine's target upside or downside calculated?
The average target of $7.30 is divided by the recorded price of $3.62, then one is subtracted to produce +101.8%. This does not guarantee a future return.
When was Prime Medicine's analyst forecast verified?
The data was verified on 2026-08-25. The dataset is valid through 2026-09-01.